Introduction
Phosphatidyl glycan biosynthesis class A protein (PIGA) is an essential enzyme involved in the glycosylphosphatidylinositol (GPI) anchor biosynthesis pathway. The GPI anchor is a glycolipid embedded in the plasma membrane which attaches to hundreds of cell surface proteins such as adhesion molecules, complement regulators and signal transduction pathway co-receptors. Germline truncating PIGA mutations have been associated with a syndrome of severe early-onset epileptic encephalopathy, profound developmental delay, dysmorphism and infantile death [1, 2] (OMIM #311770). It has been suggested that missense mutations in PIGA result in a less severe phenotype with survival beyond infancy [3] . We describe a 17 year old man with infantile epilepsy and developmental delay who has a maternally inherited missense mutation in PIGA, providing additional evidence for this hypothesis and indicating that long term survival is possible in patients with PIGA deficiency.
Clinical report
The proband [DECIPHER ID 271747] presented with epilepsy at 4 months of age. He is the only child of non-consanguineous parents. His antenatal and postnatal periods were uneventful and he was born at full term weighing 4 kg (82nd centile) and with a head circumference on the 20th centile. His seizure disorder began with short-lived versive eye movements, cyanosis and hypotonia of all four limbs. Subsequently he started to develop focal seizures with hypertonicity of his left arm and leg and these events occurred up to 30 times a day. He also had choreoathetoid movements from the time of onset of his seizures. In early childhood he had strikingly pale blond hair and normal facial features (Fig. 1) . His hair was examined by electron microscopy but no structural abnormality was found-it has become more pigmented over time. His seizure phenotype evolved during childhood to include atypical absence seizures, tonic seizures and atonic (drop) attacks. His seizures have been intractable and have not responded to anti-epileptic drugs or to a ketogenic diet. A vagal nerve stimulator (VNS) was inserted when he was 7 years old. This resulted in some improvement although his seizure management remains challenging. He had a serious episode of aspiration pneumonia resulting in an admission to the intensive care unit for several weeks.
At 17 years of age he remains wheelchair-dependent although he can sit with some support. His left hip is dislocated which may contribute to his limited mobility. He developed significant obstructive sleep apnoea which improved after adenotonsillectomy but he still requires nightly non-invasive ventilation. He has also had recurrent blepharitis requiring opthalmological surveillance and intermittent topical antibiotic treatment. His vision and hearing are normal but speech is absent, He has profound global developmental delay with regression of skills during periods of profound seizure activity.
On clinical examination he has hypotonia and choreoathetoid upper limb movements. His growth parameters are normal: height is between the 75th to 91st centiles, weight between 50th to 75th centiles and head circumference on the 50th centile. He has a scoliosis. He has pale blue eyes but no other cutaneous features. His facial features have evolved with age and may be related to his multiple anti-epileptic medications, although he has not been on phenytoin for any significant length of time.
An early MRI brain scan showed patchy areas of myelin damage with prominent CSF spaces. This suggested the possibility of a metabolic encephalopathy, in particular glutaricaciduria type 1. However extensive neurometabolic investigations have never shown any consistent abnormalities or confirmed an underlying diagnosis. Measurements of serum alkaline phosphatase on numerous occasions have been normal.
To investigate the molecular genetic basis of his condition, triobased exome sequencing was undertaken via the DDD study [4] . A novel maternally inherited variant was detected in PIGA (NM_002641.3) c.293A > C p. (Tyr98Ser). No other variants were detected. This missense variant affects a highly conserved amino acid in a known functional domain of PIGA and causes a physiochemical change which is predicted in silico to be pathogenic (Polyphen-Probably damaging 0.976; SIFT-deleterious 0.01). This specific variant has not been previously reported in the literature, and it is absent from population databases (ExAC). The clinically unaffected mother is a carrier of the variant and her X chromosome inactivation studies confirmed unilateral X-inactivation in blood of 100:0 at the HUMAR Androgen receptor. The maternal uncle, who has a history of epilepsy following a head injury but has entirely normal development, was tested and the PIGA variant was not found.
Discussion
Germline variants in PIGA have recently been associated with Xlinked inheritance of early-onset epilepsy and profound developmental delay. Johnston et al. [1] were the first authors to identify a germline truncating PIGA variant (c.1234C > T) in male infants with neonatal seizures, cleft palate, contractures, central nervous system structural malformations and early death. The boys were from different families and their mothers, who were carriers of the PIGA variant, showed skewed X-inactivation. Van der Crabben et al. 1 [5] reported a male with a missense variant (c.278C > T) who had raised alkaline phosphatase, profound developmental delay and refractory seizures and died at the age of 2.5 years. Swoboda et al.
[6] described a single male patient with a different variant (c.328_330delCCT), who also had profound developmental delay and intractable epilepsy and died aged 7 years. Belet et al. [7] reported the first non-lethal case of a profoundly developmentally delayed 24 year old male with a frameshift variant c.76dupT. He too had intractable epilepsy. Kato et al.
[8] performed whole exome sequencing for a cohort of 172 patients with early-onset epileptic encephalopathy and identified 5 PIGA variants -the previously reported truncating variant c.1234C > T and 4 novel missense variants. Tarailo-Graovac et al.
[9] reported a patient with a severe phenotype which included dysmorphic features and death at 3.4 years, who had another novel missense variant (c.989G > A). Most recently, Kim et al.
[10] reported a 'less severe' male with a missense variant (c. 427A > G) who had severe developmental delay and seizures. Although his initial developmental progress was reported to be slow, he did progress and achieved walking, albeit with an abnormal gait. Our patient has similar features to those previously reported particularly with respect to intractable epilepsy and severe intellectual disability. There is some similarity with the patient reported by Kim et al. [10] although their patient appears to have made more progress particularly with respect to motor ability. It may be that some of the reported missense mutations are hypomorphic resulting in a 'less severe phenotype'. We note that our patient did not have any congenital malformations such as cleft palate or congenital heart disease as observed in patients with truncating PIGA mutations. This would fit with the suggestion of a hypomorphic mutation resulting in a less severe phenotype and concurs with the suggestion made by Kato et al. [8] that PIGA mutations could be classified into 'severe' and 'less severe', corresponding to the degree of reduction in PIGA activity. Both involve intractable seizures and profound developmental delay but only the severe presentation includes multiple congenital anomalies and dysmorphism.
As an infant, our patient's distinctive hair led to a series of metabolic tests, but no biochemical abnormality was found and we cannot find any link to the PIGA mutation. His obstructive sleep apnoea requiring significant intervention is also an unusual feature which has not been reported in other patients, we speculate that this may be a manifestation of PIGA deficiency in central control of respiration.
PIGA deficiency was first recognized with the advent of whole exome sequencing (WES) technology. In the intervening 4 years, despite the increasing availability of WES, the number of reported patients remains below 20. The DDD study has only detected 3 cases out of 8000 trios investigated for developmental delay of unknown aetiology. It is therefore likely that PIGA deficiency is a rare cause of early onset intractable epilepsy with severe developmental delay. This diagnosis is important to consider in 
